FR2976081A1 - Methode de diagnostic de la tuberculose active - Google Patents
Methode de diagnostic de la tuberculose active Download PDFInfo
- Publication number
- FR2976081A1 FR2976081A1 FR1255119A FR1255119A FR2976081A1 FR 2976081 A1 FR2976081 A1 FR 2976081A1 FR 1255119 A FR1255119 A FR 1255119A FR 1255119 A FR1255119 A FR 1255119A FR 2976081 A1 FR2976081 A1 FR 2976081A1
- Authority
- FR
- France
- Prior art keywords
- cells
- enzyme
- lipolytic activity
- antibodies
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 62
- 208000036981 active tuberculosis Diseases 0.000 title claims abstract description 54
- 230000002366 lipolytic effect Effects 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 41
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 41
- 102000004190 Enzymes Human genes 0.000 claims abstract description 39
- 108090000790 Enzymes Proteins 0.000 claims abstract description 39
- 238000000338 in vitro Methods 0.000 claims abstract description 24
- 238000003745 diagnosis Methods 0.000 claims abstract description 17
- 108090001060 Lipase Proteins 0.000 claims description 66
- 102000004882 Lipase Human genes 0.000 claims description 66
- 239000004367 Lipase Substances 0.000 claims description 62
- 235000019421 lipase Nutrition 0.000 claims description 60
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 50
- 238000001514 detection method Methods 0.000 claims description 22
- 101100276106 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cut4 gene Proteins 0.000 claims description 21
- 150000002632 lipids Chemical class 0.000 claims description 19
- 101100385666 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cut7 gene Proteins 0.000 claims description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 108010064785 Phospholipases Proteins 0.000 claims description 11
- 102000015439 Phospholipases Human genes 0.000 claims description 11
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 10
- -1 RvO183 Proteins 0.000 claims description 8
- 230000003301 hydrolyzing effect Effects 0.000 claims description 7
- 101100276108 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cut6 gene Proteins 0.000 claims description 6
- 101000574288 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Monoglyceride lipase Proteins 0.000 claims description 6
- 101000574287 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Putative monoglyceride lipase Proteins 0.000 claims description 6
- 230000001900 immune effect Effects 0.000 claims description 5
- 210000004180 plasmocyte Anatomy 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000003720 plasmablast Anatomy 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 101100083515 Mus musculus Plcb1 gene Proteins 0.000 claims description 3
- 101100190615 Mus musculus Plcd1 gene Proteins 0.000 claims description 3
- 101100408448 Mus musculus Plcd4 gene Proteins 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 229940072221 immunoglobulins Drugs 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 abstract description 41
- 239000000090 biomarker Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 23
- 241000894006 Bacteria Species 0.000 description 18
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 101100237459 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Rv0183 gene Proteins 0.000 description 12
- 101100289186 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) lipY gene Proteins 0.000 description 11
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 10
- 230000007420 reactivation Effects 0.000 description 10
- 241000186359 Mycobacterium Species 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000003248 secreting effect Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 7
- 108010012236 Chemokines Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 229960001005 tuberculin Drugs 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 108010005400 cutinase Proteins 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 101150096059 lipC gene Proteins 0.000 description 5
- 235000019626 lipase activity Nutrition 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101100021387 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) lipC gene Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 206010065048 Latent tuberculosis Diseases 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 241000427940 Fusarium solani Species 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 101150048797 LIPH gene Proteins 0.000 description 2
- 101150058243 Lipf gene Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000187480 Mycobacterium smegmatis Species 0.000 description 2
- 101001057048 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ESAT-6-like protein EsxB Proteins 0.000 description 2
- 101100298332 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) PPE57 gene Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002190 fatty acyls Chemical class 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- DVDUMIQZEUTAGK-UHFFFAOYSA-N p-nitrophenyl butyrate Chemical compound CCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 DVDUMIQZEUTAGK-UHFFFAOYSA-N 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 102000017055 Lipoprotein Lipase Human genes 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 description 1
- 108020002334 Monoacylglycerol lipase Proteins 0.000 description 1
- 241000180044 Mycobacterium avium subsp. avium Species 0.000 description 1
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 241000961132 Mycobacterium parascrofulaceum Species 0.000 description 1
- 101100352040 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) plcA gene Proteins 0.000 description 1
- 101100352049 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) plcB gene Proteins 0.000 description 1
- 101100463891 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) plcC gene Proteins 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 108010002176 Phospholipases A Proteins 0.000 description 1
- 102000000571 Phospholipases A Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OPNPQXLQERQBBV-UHFFFAOYSA-N carbromal Chemical compound CCC(Br)(CC)C(=O)NC(N)=O OPNPQXLQERQBBV-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011998 interferon-gamma release assay Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000891 luminescent agent Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 210000004160 naive b lymphocyte Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
- REVENDICATIONS1. Méthode pour le diagnostic in vitro de la tuberculose active, comprenant : - une étape de mise en contact d'un échantillon de lymphocytes B purifiés d'un patient suspecté d'être atteint de la tuberculose active avec au moins une protéine de mycobactéries, ladite protéine étant une enzyme ayant une activité lipolytique et étant capable d'hydrolyser les lipides ayant une chaine carbonée comprenant au moins 12 carbones, ledit échantillon étant dépourvu de sérum ou de n'importe quel composé susceptible de contenir des anticorps solubles - une étape d'incubation pendant un temps dételminé pour permettre aux lymphocytes B purifies de sécréter des anticorps spécifiques dirigés contre ladite enzyme ayant une activité lipolytique, et - une étape de détection de la présence d'un complexe immun comprenant lesdits anticorps et ladite enzyme ayant une activité lipolytique.
- 2. Méthode pour le diagnostic in vitro de la tuberculose active selon la revendication 1, où ladite enzyme ayant pne activité lipolytique est choisie dans le groupe consistant en : - une monoacylglycérol hydrolase, RvO183, - une phospholipase, préférentiellement Rv3452, Rv3802c, PlcA, PlcB, PlcC ou PlcD, - la lipase Rv1984c, et - une triacylglycérol hydrolase, préférentiellement LipY.
- 3. Méthode pour le diagnostic in vitro de la tuberculose active selon la revendication 1 ou 2, où les lymphocytes B sont choisis parmi les plasmablastes et les plasmocytes.
- 4. Méthode pour le diagnostic in vitro de la tuberculose active selon l'une quelconque des revendications 1 à 3, où l'étape de détection de la présence de lymphocytes B activés consiste en la détection de la sécrétion desdites anticorps dirigés spécifiquement contre ladite enzyme ayant une activité lipolytique.
- 5. Méthode selon l'une quelconque des revendications 1 à 4, où l'étape de détection de la présence de lymphocytes B activés est mise en oeuvre par une détection immunologique.
- 6. Méthode pour le diagnostic in vitro de la tuberculose active selon l'une quelconque des revendications 1 à 5, où ledit temps dételininé est de 1 heure à 72 heures, préférentiellement de 6 heures à 48 heures, plus préférentiellement de 16 heures à 30 heures. 10
- 7. Kit pour la détection in vitro de la tuberculose active comprenant : - au moins une protéine de mycobactéries immobilisée sur un support, ladite protéine étant une enzyme ayant une activité lipolytique, - des anticorps, possiblement marqués, dirigés contre la chaine constante des 15 immunoglobulines, et - des moyens pour purifier spécifiquement des lymphocytes B. 11. Kit selon la revendication 7, où ladite enzyme ayant une activité lipolytique est capable d'hydrolyser des lipides ayant une chaine carbonée comprenant au moins 20 12 carbones. 12. Kit selon la revendication 7 ou 8, où ladite enzyme ayant une activité lipolytique est choisie dans le groupe consistant en : - une monoacylglycérol hydrolase, RvOl 83, 25 - une phospholipase, préférentiellement Rv3452, Rv3802c, P1cA, P1cB, P1cC ou P1cD, - la lipase Rv1984c, et - une triacylglycérol hydrolase, préférentiellement LipY. 30 10. Kit selon l'une quelconque des r evendications 7 à 9, où lesdits moyens pour purifier spécifiquement les lymphocytes B sont choisis parmi les anticorps spécifiques des lymphocytes B, ou les gradients de densités, ou une combinaison de ceux-ci.5
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11168643 | 2011-06-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2976081A1 true FR2976081A1 (fr) | 2012-12-07 |
FR2976081B1 FR2976081B1 (fr) | 2015-10-30 |
Family
ID=44512347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1255119A Expired - Fee Related FR2976081B1 (fr) | 2011-06-03 | 2012-06-01 | Methode de diagnostic de la tuberculose active |
Country Status (4)
Country | Link |
---|---|
US (1) | US9274110B2 (fr) |
EP (1) | EP2715363B1 (fr) |
FR (1) | FR2976081B1 (fr) |
WO (1) | WO2012164088A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105388297B (zh) * | 2013-11-25 | 2017-06-06 | 广东体必康生物科技有限公司 | 结核分支杆菌蛋白Rv1984c在制备诊断潜伏性肺结核感染的产品中的用途 |
US20170313767A1 (en) | 2014-10-21 | 2017-11-02 | The General Hospital Corporation | Methods of diagnosis and treatment of tuberculosis and infection |
EP3026121A1 (fr) | 2014-11-27 | 2016-06-01 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Diagnostic à base de micro-ARN pour la tuberculose |
FR3048286B1 (fr) | 2016-02-26 | 2021-01-22 | Omunis | Peptides immunogenes et leur utilisation |
CN106053800A (zh) * | 2016-05-30 | 2016-10-26 | 南华大学 | 一种结核病血清学诊断试剂盒 |
CN106198971A (zh) * | 2016-08-01 | 2016-12-07 | 中国疾病预防控制中心传染病预防控制所 | 结核分枝杆菌抗原蛋白Rv2351c的应用 |
CN106606774B (zh) * | 2016-11-24 | 2020-08-11 | 中国医学科学院病原生物学研究所 | 一种结核病免疫诊断分子标识及其制备疫苗的应用 |
CN107281465B (zh) * | 2017-06-02 | 2021-03-02 | 中国医学科学院病原生物学研究所 | 一种结核病疫苗候选组分以及含有该组分的疫苗 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982085B2 (en) * | 1997-04-02 | 2006-01-03 | Statens Serum Institut | TB diagnostic based on antigens from M. tuberculosis |
EP1401866A2 (fr) * | 2001-02-22 | 2004-03-31 | Institut Pasteur | Analyse comparative des genomes de mycobacteries en vue de l'identification de cibles a des fins de diagnostic, de prophylaxie ou de traitement de mycobacterioses |
GB0312037D0 (en) * | 2003-05-24 | 2003-07-02 | F2G Ltd | Phospholipase |
CA2758124A1 (fr) | 2008-04-19 | 2009-10-22 | New York University | Peptide de mycobacterium tuberculosis immunodominants provenant de proteines de paroi cellulaire pour un diagnostic precoce et une immunisation |
-
2012
- 2012-06-01 US US14/123,699 patent/US9274110B2/en not_active Expired - Fee Related
- 2012-06-01 FR FR1255119A patent/FR2976081B1/fr not_active Expired - Fee Related
- 2012-06-01 WO PCT/EP2012/060437 patent/WO2012164088A1/fr active Application Filing
- 2012-06-01 EP EP12727138.5A patent/EP2715363B1/fr not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
EP2715363B1 (fr) | 2016-09-14 |
EP2715363A1 (fr) | 2014-04-09 |
US9274110B2 (en) | 2016-03-01 |
WO2012164088A1 (fr) | 2012-12-06 |
FR2976081B1 (fr) | 2015-10-30 |
US20140220599A1 (en) | 2014-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2976081A1 (fr) | Methode de diagnostic de la tuberculose active | |
Dedieu et al. | Mycobacterial lipolytic enzymes: a gold mine for tuberculosis research | |
Da Fonseca et al. | Microbiota-dependent sequelae of acute infection compromise tissue-specific immunity | |
Naglik et al. | Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections | |
Buffet et al. | Diagnosing Treponema pallidum in secondary syphilis by PCR and immunohistochemistry | |
Mishra et al. | Functional role of the PE domain and immunogenicity of the Mycobacterium tuberculosis triacylglycerol hydrolase LipY | |
Zorrilla et al. | Isolation and characterization of the causative agent of pasteurellosis, Photobacterium damsela ssp. piscicida, from sole, Solea senegalensis (Kaup) | |
Sgaragli et al. | Human tuberculosis I. Epidemiology, diagnosis and pathogenetic mechanisms | |
Sendide et al. | Mycobacterium bovis BCG urease attenuates major histocompatibility complex class II trafficking to the macrophage cell surface | |
EP2364357B1 (fr) | Milieu et procede de culture des mycobacteries incluant les mycobacteries du complexe mycobacterium tuberculosis | |
Tallman et al. | Profiling esterases in Mycobacterium tuberculosis using far-red fluorogenic substrates | |
EP0564477B1 (fr) | Fragments de la proteine env du virus de l'immunodeficience feline, anticorps et leurs applications dans le diagnostic | |
FR2845097A1 (fr) | Procede de detection et de comptage de microorganismes dans un echantillon | |
N'goma et al. | Evidence for the cytotoxic effects of Mycobacterium tuberculosis phospholipase C towards macrophages | |
Maan et al. | Rv1288, a two domain, cell wall anchored, nutrient stress inducible carboxyl-esterase of Mycobacterium tuberculosis, modulates cell wall lipid | |
Pride et al. | Characterization of the Vibrio cholerae VolA surface-exposed lipoprotein lysophospholipase | |
EP2470907B1 (fr) | Proteines utilisees pour le diagnostic d'une borreliose de lyme | |
Srinivas et al. | Functional characterization of the phospholipase C activity of Rv3487c and its localization on the cell wall of Mycobacterium tuberculosis | |
FR2802213A1 (fr) | Bacterie "rickettsia pulicis" methode d'isolement en culture et de diagnostic serologique | |
EP2470908B1 (fr) | Proteines utilisees pour le diagnostic d'une borreliose de lyme | |
Anwar | Impact of helminth infection on antimycobacterial immune responses in UK migrants | |
EP1165750B1 (fr) | Diagnostic de la maladie de whipple | |
KR101094974B1 (ko) | 크론씨 병의 혈청학적 진단을 위한 신규한 바이오마커 | |
KR101105168B1 (ko) | 크론씨 병의 혈청학적 진단을 위한 신규한 바이오마커 | |
EP2122357A1 (fr) | Antigene digalactolipidique expose a la surface des parasites apicomplexes et ses applications diagnostiques et therapeutiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 4 |
|
TQ | Partial transmission of property |
Owner name: UNIVERSITE DE MONTPELLIER, FR Effective date: 20151117 Owner name: CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIE, FR Effective date: 20151117 Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FR Effective date: 20151117 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |
|
PLFP | Fee payment |
Year of fee payment: 9 |
|
ST | Notification of lapse |
Effective date: 20220205 |